French drugmaker Ipsen (Euronext: IPN) and the French National Center for Scientific Research are to launch the Archi-Pex (peptide architectures and formulations) joint research and innovation lab in collaboration with the French Alternative Energies and Atomic Energy Commission and the University of Rennes I.
Continuing the public-private partnership in action since 1999, the Archi-Pex lab seeks to conduct multi-disciplinary research by academic teams and researchers at Ipsen’s center for pharmaceutical development at Dreux in France.
The aim is to innovate in formulating hormonal peptides and reduce development time.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze